You are here

FDA Grants Telcyta Fast Track Designation

PALO ALTO, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) announced that the U.S. Food and Drug Administration has granted Fast Track designation for TELCYTA(TM) (TLK286) for third line therapy in patients with platinum refractory or resistant ovarian cancer.

"Fast Track designation is a recognition by the FDA of the serious unmet medical need faced by women with platinum refractory or resistant ovarian cancer, and the potential of TELCYTA(TM) to address that need," said Gail L. Brown, M.D., senior vice president and chief medical officer. A randomized Phase 3 registration clinical trial with TELCYTA(TM) is in progress for third line therapy in patients with platinum refractory or resistant ovarian cancer.

Fast Track programs are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life- threatening conditions and that demonstrate the potential to address unmet medical needs.

About Ovarian Cancer and TELCYTA(TM)
Approximately 25,400 new cases of ovarian cancer will be diagnosed in 2003, according to the American Cancer Society. Ovarian cancer causes more deaths than any other cancer of the female reproductive system.

Source: Telik, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation